QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

$13.05
+0.69 (+5.58%)
(As of 04:22 PM ET)
Today's Range
$12.41
$13.20
50-Day Range
$11.48
$15.86
52-Week Range
$5.27
$27.97
Volume
345,502 shs
Average Volume
524,016 shs
Market Capitalization
$805.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.58

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
49.4% Upside
$19.58 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Treace Medical Concepts in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.91) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Medical Sector

651st out of 938 stocks

Surgical & Medical Instruments Industry

65th out of 97 stocks

TMCI stock logo

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

TMCI Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Treace Medical Concepts Inc
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
TMCI Sep 2024 20.000 call
TMCI Jun 2024 22.500 call
TMCI Mar 2024 17.500 call
TMCI Mar 2024 25.000 call
Treace Medical Concepts Inc (TMCI)
BTIG Reaffirms Their Buy Rating on Treace Medical Concepts (TMCI)
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
516
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.58
High Stock Price Target
$27.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+58.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-49,530,000.00
Pretax Margin
-26.47%

Debt

Sales & Book Value

Annual Sales
$187.12 million
Book Value
$2.24 per share

Miscellaneous

Free Float
44,037,000
Market Cap
$763.35 million
Optionable
Optionable
Beta
0.28
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 52)
    CEO, Founder & Director
    Comp: $1.04M
  • Mr. Mark L. Hair CPA (Age 54)
    Chief Financial Officer
    Comp: $628.6k
  • Mr. Aaron J. Berutti (Age 45)
    Senior Vice President of Sales
    Comp: $519.41k
  • Mr. Terry W. Lubben (Age 59)
    Senior Vice President of Operations
  • Ms. Julie D. Dewey (Age 63)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder (Age 49)
    Chief Legal & Compliance Officer and Corporate Secretary
  • Mr. Nathan Minnich
    Senior Vice President of Marketing
  • Mr. Daniel E. Owens (Age 52)
    Chief Human Resources Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 41)
    Chief Innovation Officer
  • Ms. Shana Zink
    Senior Vice President of Clinical Affairs, Medical Education & Reimbursement

TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price target for 2024?

6 brokerages have issued 12 month price targets for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they predict the company's stock price to reach $19.58 in the next twelve months. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2024?

Treace Medical Concepts' stock was trading at $12.75 at the beginning of the year. Since then, TMCI stock has increased by 2.8% and is now trading at $13.11.
View the best growth stocks for 2024 here
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The firm earned $62.20 million during the quarter, compared to analysts' expectations of $60.56 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 33.96% and a negative net margin of 26.47%. The business's revenue was up 24.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.08) earnings per share.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220.0 million-$225.0 million, compared to the consensus revenue estimate of $223.2 million.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.96%), Vanguard Group Inc. (6.95%), Armistice Capital LLC (4.63%), TimesSquare Capital Management LLC (2.84%), CIBC Private Wealth Group LLC (2.37%) and Perceptive Advisors LLC (2.03%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends
.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners